Publication: 258

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
      Google Scholar   
Citation:
Cancer vol 113 (11) 3137-45
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
504  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
CA16359, CA21060, CA33601, CA60138, CA77651  
Corr. Author:
 
Authors:
               
Networks:
 
Study
CALGB-99811
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Aged, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Combined Modality Therapy, Disease-Free Survival, Drug Administration Schedule, Estramustine, Feasibility Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Paclitaxel, Prostate-Specific Antigen, Prostatic Neoplasms